Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound Paclitaxel, Lenvatinib, and Pembrolizumab in Advanced Nonsquamous NSCLC
NCT06028633Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors, Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib, nab-paclitaxel in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Peking University First Hospital. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT06028633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06028633.